Previous 10 | Next 10 |
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights PR Newswire SAN DIEGO , Aug. 7, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical...
2023-05-30 09:33:22 ET Inhibrx, Inc. ( NASDAQ: INBX ) announced Tuesday that the FDA granted Fast Track designation for its experimental therapy INBRX-101 as a treatment for patients with emphysema due to alpha-1 antitrypsin deficiency (AATD). Characterized by damaged air sacs...
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency PR Newswire SAN DIEGO , May 30, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of ...
2023-05-08 17:03:19 ET Inhibrx press release ( NASDAQ: INBX ): Q1 GAAP EPS of -$1.12. Cash and Cash Equivalents. As of March 31, 2023, Inhibrx had cash and cash equivalents of $234.3 million, compared to $273.9 million as of December 31, 2022. For further d...
Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights PR Newswire SAN DIEGO , May 8, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four clinical programs in developme...
2023-05-04 16:20:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2023, Baron Health Care Fund declined 3.69%, compared w...
Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials PR Newswire SAN DIEGO , April 26, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutica...
Inhibrx ( NASDAQ: INBX ) on Wednesday reported updated data from an ongoing phase 1 trial of INBRX-109 expansion groups to treat chondrosarcoma. Chondrosarcoma is a rare cancer which usually begins in the bones, but can at times occur in the soft tissue near the bones. ...
Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma PR Newswire SAN DIEGO , Nov. 16, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopha...
Inhibrx press release ( NASDAQ: INBX ): Q3 GAAP EPS of -$0.90 beats by $0.04 . Revenue of $0.28M (-88.9% Y/Y) misses by $0.29M . For further details see: Inhibrx GAAP EPS of -$0.90 beats by $0.04, revenue of $0.28M misses by $0.29M
News, Short Squeeze, Breakout and More Instantly...
Inhibrx Inc. Company Name:
INBX Stock Symbol:
NASDAQ Market:
2024-07-23 06:30:08 ET JMP Securities analyst issues MARKET PERFORM recommendation for INBX on July 23, 2024 04:40AM ET. The previous analyst recommendation was Outperform. INBX was trading at $13.49 at issue of the analyst recommendation. The overall analyst consensus :...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...